Clinical trials: First Line Treatment
Breast Adenocarcinoma, HER2/Neu Negative
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back.
- Conditions
- Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7
- Trial name
- NCT02037529
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 39 sites in United States
- Volunteers
- 201 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
The drugs FEC 100 (5-fluorouracil, epirubicin, and cyclophosphamide) are one of the approved options to treat Locally Advanced or Primary Metastatic Breast Cancer.
- Trial name
- VPA-FEC100 (NCT01010854)
- Testing
- VPA FEC100
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
In the past, patients with advanced lung cancer who were inoperable underwent chemotherapy with one or more chemotherapeutic agents.
- Trial name
- NCT00998166
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Carcinoma, Hepatocellular
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no…
- Trial name
- NCT02859324
- Testing
- CC-122, Nivolumab
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach…
- Trial name
- RAINFALL (NCT02314117)
- Testing
- Ramucirumab, Capecitabine, Cisplatin
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 645 people
- Sponsor
- Eli Lilly and Company
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objectives of the study are: To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell…
- Conditions
- Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
- Trial name
- NCT03088540
- Testing
- Pemetrexed, Paclitaxel, Gemcitabine
- Where
- 192 sites in Australia, Belarus and 22 more
- Volunteers
- 712 people
- Sponsor
- Regeneron Pharmaceuticals
Aneurysm
Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic
To assess the safety and efficacy of the GORE Conformable TAG® Thoracic Endoprosthesis in the primary treatment of aneurysm of the descending thoracic aorta (DTA) > Primary Hypothesis: The proportion of subjects free from a major…
- Trial name
- NCT00874250
- Testing
- GORE CTAG Device
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- W.L.Gore & Associates
Pleural Mesothelioma Malignant Advanced
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma.
- Trial name
- BEAT-meso (NCT03762018)
- Testing
- Carboplatin, Pemetrexed, Bevacizumab
- Where
- 42 sites in Belgium, France and 4 more
- Volunteers
- 400 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non-Small Cell Lung Cancer
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
- Trial name
- NCT00130728
- Testing
- bevacizumab, erlotinib HCl
- Where
- 4 sites in United States
- Volunteers
- 636 people
- Sponsor
- Genentech, Inc.
Breast Cancer Metastatic
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination…
- Trial name
- NCT05155566
- Where
- 2 sites in Argentina, United Kingdom
- Volunteers
- 847 people
- Sponsor
- Pfizer
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
This 2 arm study will evaluate the efficacy and safety of Avastin + gemcitabine, and Avastin + gemcitabine + attenuated doses of cisplatin, as first line treatment in elderly patients with non-squamous non-small cell lung cancer.
- Trial name
- NCT01077713
- Testing
- bevacizumab [Avastin], cisplatin, gemcitabine
- Where
- 26 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
BRAF V600E Mutation Positive, Metastatic Colorectal Cancer
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in patients with mCRC, and findings from clinical trials have largely remained inconclusive regarding the efficacy of first line treatments for…
- Trial name
- CAPSTAN CRC (NCT04317599)
- Testing
- Non interventional
- Where
- 34 sites in Austria, Belgium and 5 more
- Volunteers
- 274 people
- Sponsor
- Pierre Fabre Medicament
Metastatic Colorectal Cancer
A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type…
- Trial name
- TAILOR (NCT01228734)
- Testing
- Cetuximab, Oxaliplatin, Folinic Acid
- Where
- 25 sites in China
- Volunteers
- 553 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Stage IV or Recurrent Non-Small Cell Lung Cancer
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
- Trial name
- NCT02041533
- Testing
- Nivolumab, Gemcitabine, Cisplatin
- Where
- 141 sites in United States, Argentina and 24 more
- Volunteers
- 541 people
- Sponsor
- Bristol-Myers Squibb
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer…
- Trial name
- TIME (NCT01664533)
- Testing
- Erlotinib
- Where
- 21 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer
Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
As < 10% of the necessary patients required by the protocol were recruited and the data were not intended to support a labeling claim, it was determined that the abbreviated clinical study report (CSR) was the appropriate…
- Trial name
- CANVAS (NCT01521143)
- Testing
- Cvac
- Where
- 8 sites in United States, Australia
- Volunteers
- 91 people
- Sponsor
- Prima BioMed Ltd
Merkel Cell Carcinoma
Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC).
- Trial name
- NCT03783078
- Testing
- Pembrolizumab (MK-3475)
- Where
- 22 sites in United States, Australia and 6 more
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer, Carcinoma
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma
- Trial name
- ABOUND 70+ (NCT02151149)
- Testing
- nab-paclitaxel, Carboplatin
- Where
- 55 sites in United States
- Volunteers
- 143 people
- Sponsor
- Celgene